ABBV-744

Overview

ABBV-744 is a first-in-class, orally active and selective inhibitor of the BDII domain of BET family proteins with IC 50 values ranging from 4 to 18 nM for BRD2, BRD3, BRD4 and BRDT. ABBV-744 is primarily metabolized by CYP3A4 with agent-like properties enable the investigation of its antitumor efficacy and tolerability.

Application

Products | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Viral Infection | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Epigenetic Reader Domain | Products > Signaling Pathways > HIV

Product Information

• Catalog No.: HY-112090
• CAS No.: 2138861-99-9
• Molecular Formula: C28H30FN3O4
• Molecular Weight: 491.55
• Purity: 99.97%
• Storage: 4°C, stored under nitrogen * In solvent : -80°C, 1 year; -20°C, 6 months (stored under nitrogen)
• Solubility: ≥ 2.5 mg/mL (5.09 mM); Clear solution
• Availability: In-stock

Source

Original product source